Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05531591 · ClinicalTrials.gov registry record · Phase 4
RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)
A Phase 4 study, sponsored by Centre for Addiction and Mental Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 87
- Enrollment target
NCT05531591 is a Phase 4 study that has completed, run by Centre for Addiction and Mental Health. The registered enrollment target is 87 participants.
The verdict
NCT05531591, a Phase 4 study, has completed, sponsored by Centre for Addiction and Mental Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD), and to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.
Interventions
- DRUG Aripiprazole Augmentation
- DRUG Bupropion Augmentation
- DRUG Switch to bupropion
- DRUG Lithium Augmentation
- DRUG Switch to nortriptyline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05531591
The ClinicalTrials.gov registry entry for NCT05531591 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centre for Addiction and Mental Health, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aripiprazole Augmentation is the first listed.
NCT05531591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05531591 about?
NCT05531591 is a clinical study titled "RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)". The purpose of this study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD), and to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.
What is the current status of trial NCT05531591?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2019-08-01. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05531591?
The interventions under investigation include: Aripiprazole Augmentation (DRUG), Bupropion Augmentation (DRUG), Switch to bupropion (DRUG), Lithium Augmentation (DRUG), Switch to nortriptyline (DRUG).
Who is sponsoring clinical trial NCT05531591?
This trial is sponsored by Centre for Addiction and Mental Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.